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Introduction
Glioma is the most common primary brain tumor in 
adults and glioblastoma multiforme (GBM) is the most 
aggressive of all human tumors which eventually have 
a very poor prognosis (Ni et al., 2014; Pashaki et al., 
2014; Qin et al., 2015). In spite of multiple treatment 
strategies including surgery, external radiation therapy 
and chemotherapy (Qin et al., 2013), the average survival 
of these patients is about 6-11 months (Davis et al., 
1998; Farah et al., 2016) and even less than 6 months 
in recurrent cases. GBM is more common in men than 
women (male to female ratio: 1.58 to 1) and the average 
age at the time of diagnosis is about sixty four (States, 
2010). Glioblastoma is one of the most highly angiogenic 
solid tumors that its vasculature is both structurally and 
functionally abnormal (Weathers and de Groot, 2015). 
The improper vasculature enhances tumor hypoxia and 
impairs the delivery of cytotoxic chemotherapy (Weathers 
and de Groot, 2015). Copper is an essential trace mineral 
that its concentration is high in blood-rich organs such as 
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liver, brain, heart and kidney, also known as an important 
mediator of angiogenesis (Hanahan and Folkman, 1996; 
Urso and Maffia, 2015). Copper reduction inhibits 
experimentally the growth and invasiveness of Glioma 
(Brem et al., 2005). Copper ions stimulate proliferation 
and migration of the endothelial cells through the 
induction of fibronectin synthesis (Hanahan and Folkman, 
1996). Penicillamine is a chelating agent used to treat 
intracerebral copper overload in Wilson’s disease (Brem 
et al., 2005). A broad collection of cytokines displays 
modified expression in cancers, including glioblastoma 
multiforme (Albulescu et al., 2013). In the process of 
angiogenesis, several factors such as IL-6, TNF-α, VEGF, 
IL-8 and TGF are involved (Fukumura and Jain, 2007; 
Riaz et al., 2014). It is reported that a number of growth 
factors and cytokines have angiogenic activity; these 
include VEGF, bFGF (basic fibroblast growth factor), 
EGF (epidermal growth factor), TGF (transforming 
growth factor)-β, IL-6, IL-8, IL-1 and TNF-α (Mihara et 
al., 2012; Raluca et al., 2014). IL-6 has been implicated 
in the regulation of growth and differentiation in many 
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cancers, and is associated with poor prognosis (Mihara et 
al., 2012) and its overproduction has been implicated in the 
pathogenesis of a variety of diseases, including numerous 
chronic inflammatory diseases and cancer (Mihara et al., 
2012). In glioblastoma, IL-6 has been associated with 
tumor cell proliferation, invasion, angiogenesis, immune 
suppression, and poor prognosis (Anton and Glod, 2014). 
IL-6 enhances the expression of adhesion molecules 
such as VCAM (vascular cell adhesion molecule)-1 and 
ICAM-1 (intercellular adhesion molecule-1) in inflamed 
sites and endothelial cells (Mihara et al., 2012). IL-6 
is a key tumor-promoting cytokine produced by both 
malignant and host cells in the tumor microenvironment 
(Gopinathan et al., 2015) and is an important regulator of 
cell survival, providing tumor cells with a mechanism to 
escape cell death induced by stress and cytotoxic drugs 
(Mihara et al., 2012). IL-6 level is lower in the central 
portion of tumors (Chang et al., 2013). These data suggest 
a role for IL-6 in promoting invasion and metastasis. 
Therefore IL-6 blockade is anticipated to constitute a 
new treatment strategy for inflammatory and autoimmune 
diseases, as well as for cancers.
IL-6 is as potent as VEGF in inducing vessel sprouting 
and was also able to stimulate endothelial cell migration 
and proliferation (Gopinathan et al., 2015). VEGF plays 
a crucial role in IL-6-induced angiogenesis (Mihara et 
al., 2012). VEGF acts by different mechanisms such 
as induction of endothelial cells to form capillary-like 
structures and enzyme secretion for degradation of 
extracellular matrix and also increases the survival 
of tumoral cells by expressing anti-apoptotic proteins 
such as BcL-2 and its homologous A1 (Zhang et al., 
2013; Kumar et al., 2016). TNF-α, a pro-inflammatory 
cytokine, is expressed in ischemic and injured tissues 
(Kwon et al., 2013). Effects of TNF-α on angiogenesis 
and vasculogenesis already have shown in experimental 
models (Kwon et al., 2013). TNF-α induces angiogenesis 
by NF-kappaB signaling pathway. Nuclear factor-kappaB 
(NF-kappaB) is a critical transcription factor that 
contributes to cancer development by regulating a number 
of genes involved in angiogenesis and tumorigenesis 
(Kim et al., 2010). TNF-α induces activity and expression 
of matrix metalloproteinase-9 (MMP-9), and cell-
surface expression of intercellular adhesion molecule-1 
(ICAM-1), which is associated with adhesion of 
leukocytes to endothelial cells (Yang et al., 2014). 
TNF-α leads to upregulation of VEGF and following 
upregulation of MMP-2 and MMP-9 production, and 
promote angiogenesis via pathways involving PI3K 
( phosphatidylinositol 3-kinase) and NF-κB (Shin et al., 
2015). VEGF and TNF-α can induce angiogenesis. TNF-α 
affects on the expression of VEGF and these factors 
both result in angiogenesis (Chen et al., 2005). TNF-α 
stimulates blood perfusion and inhibits ischemic tissue 
damage in an IL-6- and IL-8-dependent mechanisms 
(Kwon et al., 2013).
Gamma knife radiosurgery utilizes highly accurate 
radiation techniques to allow dose escalation and delivery 
of ablative radiation doses to tumor by affecting vascular 
endothelium, while minimizing dose to the adjacent 
normal organs (Redmond and Mehta, 2015). Stereotactic 
radiosurgery (SRS) may be used as a considerable 
treatment option in the patients recurring after surgery, 
external radiotherapy and chemotherapy (Koca et al., 
2014; Redmond and Mehta, 2015). Because glioblastoma 
shows the highest degree of angiogenesis among all human 
tumors (Brem et al., 2005), in this randomized clinical trial 
we have investigated whether reducing serum copper and 
consequently brain copper (by combination of low copper 
diet and penicillamine), associated with gamma knife 
radiosurgery could have a synergistic effect on survival 
rate and also inhibit angiogenic factors VEGF, IL-6 and 
TNF-α in GBM.
Materials and Methods
This clinical trial was designed to add a low-risk 
method to the treatment of patients suffering from 
recurrent glioblastoma which have not any specified 
and definite way to improve survival rate despite many 
efforts and researches. The study protocol approved by 
Tehran University of Medical Sciences Ethics Committee 
(Approval number: 9209161).
Patients and Treatment
The patients with recurrent GBM who were candidate 
for gamma knife radiosurgery, after obtaining written 
consent and according to the following inclusion criteria 
were randomly divided into two intervention and 
placebo groups: pathologically confirmed glioblastoma 
multiforme by open surgery or biopsy; tumor recurrence 
after operation, radiotherapy or chemotherapy; age≥ 18.0; 
Karnofsky performance score (KPS)≥ 60.0 based on 
Table 1 (Milstein et al., 1985); ability to provide written 
consent; proper hematological, renal and hepatic function. 
Before intervention, laboratory tests were performed and 
patients with following criteria were included: WBC≥ 
4,000.0/mm3, Hb≥ 10.0 g/dl, platelets≥ 100,000.0/mm3, 
BUN≤ 40.0, creatinine≤ 1.5mg, AST and ALT≤ 4.0 
folds normal, PT and PTT< 1.5 folds normal and serum 
copper 70.0-150.0µg/dl. The Karnofsky Performance 
Status Scale (KPS) is the most widely used method of 
quantifying the functional status of cancer (Mor et al., 
1984). The KPS is an11-point rating scale which ranges 
from normal functioning (100.0) to dead (0.0). Exclusion 
criteria: Pregnancy; breast feeding; oral contraceptive use; 
sensitivity to penicillin; hepatic, renal or hematological 
insufficiency; concomitant use of  Avastin (Bevacizumab) 
or any investigational agent. All two group of patients 
also received desired therapy consisting of gamma 
knife radiosurgery followed by adequate drugs such as 
anticonvulsant and corticosteroid. Using a randomized 
block design, patients were divided into intervention 
and placebo group. Weight, height, BMI and KPS of all 
patients were measured and also in a non-fasting state, 
10.0 ml blood sample was taken and serum was separated 
and frozen in -70.0 ˚C to measure biomarkers such as 
IL-6, TNF-α and VEGF by ELISA (enzyme-linked 
immunosorbent assay) test. Duration of the intervention 
was three months and patients were followed for 12.0-24.0 
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prescribed low copper diet for three months. A dietwith a 
limit of 0.5 mg of copper per day was developed. Foods 
high in copper (organ meat including liver; heart; brain, 
shellfish, bran bread, mushrooms and chocolate) were 
replaced with foods low in copper to provide adequate 
micronutrients and calories (Brem et al., 2005). The 
researcher called the patients every week; a diary of food 
intake of three days was used to confirm compliance with 
the diet at first and end of study. The serum copper level 
was used as the ultimate index of compliance with the diet.
Statistical Methods
Data were analyzed using SPSS version 23 software 
(SPSS Inc., Chicago, IL). The Kolmogorov–Smirnov test 
(KS test) was used to test normal distribution of data. 
Student’s t-test was adopted to compare two groups at 
the beginning and end of the study. For each group, we 
compared baseline with final measurement using paired 
t-test. Kaplan-Meier model was used to compare overall 
survival rates between the two groups. Failure rate was 
calculated as the numbers of deaths divided by total follow 
up time. All reported P values were two-sided.
Results
Sixty three patients with recurrent glioblastoma 
assessed for eligibility for the study. Thirteen of them 
were excluded after the initial interview and laboratory 
tests, 9 patients not met inclusion criteria and 4 refused to 
follow participation (Figure 1). All of 50 selected patients 
had pathologically confirmed diagnosed glioblastoma 
multiforme (48 patients by open surgery and 2 patients 
with stereotactic biopsy). Patients were allocated to 
intervention and placebo group. The sample size was 
21 patients in each group; with a 20% risk of loss, 25 
persons allocated in intervention and 25.0 in placebo 
group. Unfortunately 6 patients (12%) died before the end 
of 3.0 months intervention period; four of which in the 
placebo and two patients were in the intervention group. 
Of the remaining 44 patients, 26 men and 18 women 
(59% and 41% respectively) followed the study. Patients’ 
characteristics at entry according to sex, age and KPS are 
listed in Table 2.
The amount of copper used in the intervention group 
was reduced which was measured by food diary method. 
Reduction in serum copper was clinically tolerable 
throughout the study for the patients. In one patient, 
hemoglobin decreased below normal level that improved 
by reduction of penicillamine dose to 500 mg per day. 
One patient underwent debulking operation in the course 
of intervention. None of the patients developed skin, 
liver and bone complications. After 6 weeks (middle of 
the study), both intervention and placebo groups were 
examined clinically and paraclinically. Mean serum 
copper level was significantly decreased in intervention 
group compared to placebo group (86.8 ± 2.9 vs. 118.3 ± 
3.4, P < 0.001) (Table 3). IL-6 and VEGF in intervention 
group were significantly decreased compared to placebo 
group (P< 0.001). For IL-6 mean ± SE, 1.4 ± 0.1 vs. 2.2 ± 
0.2; (data not shown for VEGF). Level of TNF-α was not 
months. Intervention began on the same day as the start 
of gamma knife radiosurgery, using an initial dose of 
250 mg daily of penicillamine or placebo, with dose 
escalation every other day for one week to reach final 
dose of 1gr per day. For both intervention and placebo 
group, radiosurgery at a dose of 16 to 18 Gray (1,600 
to 1,800 cGy) with 50% isodose in singlefractionwas 
performed. In intervention group, a low-copper diet was 
used simultaneously with penicillamine. Patients in the 
placebo group were asked to continue their usual diet.
Pyridoxine, 40mg orally daily was given during the study 
to prevent the seizure secondary to vitamin B6 deficiency 
due topenicillamine consumption (Brem et al., 2005). 
In order to control probable side effects of intervention, 
laboratory tests including CBC, PT, PTT, BUN, Cr, AST, 
ALT and serum copper were conducted in the beginning, 
middle and end of the study.
Nutritional Intervention: Low-Copper Diet
Patients in the intervention group were asked to follow 
Performance Score
Normal 100
Normal activity; minor signs/symptoms of disease 90
Subnormal activity; some signs/symptoms of 
disease
80
Self-care; unable to work and unable to continue 
normal
70
Requires occasional assistance 60
Requires considerable assistance and frequent 
medical care
50
Disabled; requires special care 40
Severely disabled hospitalized 30
Very sick hospitalized with active support treatment 20
Moribund 10
Dead 0
Table 1. Karnofsky Performance Score
Figure 1. Flow Chart for the Study Subjects.
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significantly increased in intervention group (Mean ± SE, 
10.8 ± 0.9 vs. 12.5± 1.3; P=0.263) while it was increased 
significantly in placebo group (Mean ± SE, 12.6 ± 0.9 vs. 
16.8 ± 1.5; P=0.018). (Table 3). Twenty four months after 
starting intervention, twenty of the 44 patients accrued to 
this clinical trial have died. Nine patients in intervention 
group and 11 in placebo group. Total follow up time in 
this study was 29.8 patient-years in intervention group 
and 22.6 in placebo group. The failure rate in intervention 
and placebo groups was 0.3 vs. 0.5 respectively. Overall 
survival time was 17.1 (95% CI, 15.6-21.4) months. Mean 
survival in intervention and placebo group were 18.5 and 
14.9 months respectively. Overall survival in intervention 
group was improved however there was no significant 
(Figure 2).
Discussion
Earlier, animal studies have shown that copper 
reduction can suppress malignant tumor growth and 
angiogenesis (Yoshida et al., 1995). We evaluated copper 
reduction by combining penicillamine with a nutritional 
method along with gamma knife radiosurgery, as a novel 
approach for treatment of recurrent glioblastoma at patients 
who have previously failed to respond to other treatments 
and have a survival rate less than 6 months . Only in one 
human study low copper diet and penicillamine was given 
to a number of patients with newly diagnosed GBM who 
had undergone conventional radiotherapy and the results 
were compared with a reference group (New Approaches 
to Brain Tumor Therapy (NABTT) CNS Consortium) 
that did not increase survival (Brem et al., 2005). In our 
study, patients suffering from recurrent GBM who were 
previously treated with open surgery and conventional 
radiotherapy (with or without chemotherapy) and now 
are candidate for gamma knife radiosurgery as one of 
the last palliative treatment modalities, were exposed 
to a safe, tolerable and feasible intervention. Nearly all 
patients cooperated with research team. In addition the 
placebo group was not deprived of desired treatment, the 
gamma knife radiosurgery. Up to this time, there have 
been few antiangiogenesis agents suitable for cancer 
therapy. Penicillamine was previously demonstrated 
to have antineoplastic (Wadhwa and Mumper, 2013) 
and antiangiogenic effects (Antoniades et al., 2013) in 
laboratory investigations, but it has been used rarely in 
clinical trials against human cancer such as malignant 
brain tumors (Brem et al., 2005) and had not encouraging 
results to increase survival rate. In this study, we used a 
nutritional intervention (reduction of copper as an essential 
micronutrient) accompanied by a precise radiation 
modality that discharges a high dose energy to the tumor 
and targets its vascular structures as the innovative 
aspect of the study. In gamma knife radiosurgery an 
accurate and high dose of gamma radiation (16-18Gy; 
BED [Biological Effective Dose] = 41.6-50.4Gy) is 
focused in the tumor center whereas area around the 
lesion receives a lower dose. Regarding to the invasive 
and highly malignant nature of glioblastoma, regrowth 
of malignant cells is probable and the margin of tumor 
where there is less gamma ray penetrated is one of the 
possible areas. So we tried to reduce copper, in order to 
minimize angiogenesis in the tumor margin where there 
is the most potential risk for tumor expansion. Also in this 
study the use of penicillamine and low copper diet was 
well tolerated by most patients and some complications 
were resolved by dose reduction or repletion of copper. 
We did not observe adverse reactions such as cerebral 
Characteristics * Intervention group (n=23) Placebo group (n=21) p
Sex(male) 14.0 (60.9%) 12.0 (57.1%) 0.8
Age(years) 44.8 ± 2.5 42.5 ± 2.5 0.51
Karnofsky performance score (KPS) 75.2 ± 2.4 74.8 ± 2.4 0.89
Table 2. Patient Characteristics
*Data are presented as Mean ± Standard Error of Mean (SE)
Variable Intervention (Mean ± SE) Placebo (Mean ± SE) P
IL-6 (pg/ml) Before 2.3 ± 0.3 2.3 ± 0.2 0.77
After 1.4 ± 0.1 2.2 ± 0.2 < 0.001
TNF-α (pg/ml) Before 10.8 ± 0.9 12.6 ± 0.9 0.19
After 12.5 ± 1.3 16.8 ± 1.5 0.038 
Copper( µg/dl) Before 116.2 ± 5.4 116.4 ± 3.5 0.98
After 86.8 ± 2.9 118.3 ± 3.4 < 0.001
Table 3. Patients’ Serum Levels of Cytokines and Copper
Figure 2. Overall Survival (Kaplan-Meier Curves) for 
Intervention Group (Solid Line) Compared to Placebo 
Group (Broken Line).
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hemorrhage, thrombosis, cutaneous and hematological 
toxicity or neurological impairment. In this study, 
three important factors in angiogenesis, VEGF, IL-6 
and TNF-α were assessed. Improper tumor vasculature 
enhances tumor hypoxia (Weathers and de Groot, 2015). 
Angiogenesis advances by both hypoxia-dependent and 
hypoxia-independent mechanisms (Carmeliet, 2005). 
Hypoxia activates hypoxia-inducible factor-1α (HIF-
1α) that leads to activation of VEGF, one of the most 
important regulators of angiogenesis (Kaur et al., 2005). 
Hypoxia-independent mechanisms including Ras/mitogen 
activated protein kinase and phosphatidylinositol 3-kinase 
also upregulate VEGF. Mouse endothelial cell tube 
formation assay showed that anti-TNF-α monoclonal 
antibody could inhibit blood vessels formation directly 
and indirectly (Liu et al., 2015). Furthermore, the 
human-specific TNF-α antibody significantly inhibits in 
vivo angiogenesis, tumor growth and metastasis (Lai et 
al., 2016).
 In addition to VEGF, IL-6 and TNF-α, glioblastoma 
usually expresses other proangiogenic factors such 
as platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), and interleukin-8 (Schmidt et al., 
1999; Brat et al., 2005; Reiss et al., 2005; Wang et al., 
2008) so blocking these elements or their receptors can 
inhibit the expression of their signals (Yu et al., 2013). 
Copper reduction impairs function of the angiogenic 
factors such as VEGF and its receptors, VEGFR-1 and 
VEGFR-2 which are the main and primary activators of 
angiogenesis (Hanahan and Folkman, 1996; Fukumura 
and Jain, 2007; Xu et al., 2015) and inactivates cytokines 
such as IL-8, IL-6, TNFα and PG. It has already reported 
that low copper diet and penicillamine can inhibit glioma 
cell growth in animal model (Yoshida et al., 1995). Also 
reduced copper inhibits the angiogenic response induced 
by the human brain tumor cells (Nasulewicz et al., 2004). 
Since angiogenesis is a critical factor in the growth of 
some tumors such as glioblastoma and copper is a known 
regulator of angiogenesis (Brem et al., 2005), this study 
describes serum copper reduction by nutritional and 
pharmacological intervention may inhibit glioblastoma 
growth. Our study suggests that reduction of IL-6, TNF-α 
and VEGF along with copper depletion probably decreases 
tumor angiogenesis, expansion and invasiveness. Also 
the study demonstrates practical achievement to serum 
copper reduction as a safe and inexpensive procedure for 
one of the most malignant human tumors. The horizon 
of anti-angiogenesis research demonstrates opportunity 
in regard to brain cancer. Angiogenesis inhibitors seem 
likely to become a leading part of therapeutic strategies 
aimed at invasive tumors such as GBM. However further 
work is nedded to understand other complex mechanisms 
involved in angiogenesis.
According to our observations, it seems that reducing 
the level of copper by diet and penicillamine that was 
accompanied by a decrease in angiogenesis-related factors 
such as VEGF, IL-6 and TNF-α, may lead to decline in 
angiogenesis as a main phenomenon of tumor spread. 
To better understand the possibilities of antiangiogenic 
tumor therapy and to assess possible side effects further 
investigations will be needed.
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